Agraban
Agraban Uses, Dosage, Side Effects, Food Interaction and all others data.
Agraban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
Agraban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Agraban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy.
| Trade Name | Agraban |
| Availability | Prescription only |
| Generic | Tirofiban |
| Tirofiban Other Names | Tirofiban, Tirofibán, Tirofibanum |
| Related Drugs | clopidogrel, Plavix, Brilinta, enoxaparin, ticagrelor, Lovenox |
| Weight | 5mg |
| Type | Infusion |
| Formula | C22H36N2O5S |
| Weight | Average: 440.597 Monoisotopic: 440.234492962 |
| Protein binding | 65% |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Agraban is a platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome.
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
Agraban is also used to associated treatment for these conditions: Cardiovascular Events
How Agraban works
Agraban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban.
Food Interaction
No interactions found.Agraban Hypertension interaction
[Major] The use of gp11b<111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (
Agraban Drug Interaction
Major: enoxaparin, heparin, clopidogrelModerate: aspirinUnknown: epinephrine, albumin human, spironolactone, RHO Immunoglobulin , insulin glulisine, hydralazine, phytonadione, amoxicillin / clavulanate, sulfamethoxazole / trimethoprim, glucose, isosorbide mononitrate, furosemide, atorvastatin, multivitamin, sodium chloride, acetaminophen
Agraban Disease Interaction
Volume of Distribution
- 22 to 42 L
Half Life
2 hours
Clearance
- 213 - 314 mL/min [Healthy subjects]
- 152 - 267 mL/min [patients with coronary artery disease]
Elimination Route
It is cleared from the plasma largely by renal excretion, with about 65% of an administered dose appearing in urine and about 25% in feces, both largely as unchanged tirofiban.
Innovators Monograph
You find simplified version here Agraban
